Danaher, a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service.
Sawyer Montgomery, currently Vice President and Group Executive of Danaher's Clinical Diagnostics businesses, will become an executive officer of Danaher reporting to President and Chief Executive Officer, Rainer Blair.
"Julie's exceptional leadership has been instrumental in driving growth and improving performance at Beckman Coulter Diagnostics and, more recently, across our Clinical Diagnostics businesses. During her tenure Julie has shown tremendous commitment to supporting our customers, building winning teams, driving innovation and leading with the Danaher Business System. I look forward to seeing Julie apply her skills and experiences to help ensure the ongoing success of our entire Diagnostics franchise, as we work to improve outcomes for patients with faster, more accurate diagnoses," said Blair.
Sawyer Montgomery joined Danaher in 2017. In her current role, she is responsible for providing strategic leadership across Danaher's Diagnostics businesses. Previously, she held positions of increasing responsibility and was the President of Beckman Coulter Diagnostics. Before joining Danaher, Ms. Sawyer Montgomery held leadership roles at Hospira Infusion Systems, Boston Scientific and Boston Consulting Group. She holds a Bachelor of Arts in Economics from Columbia University, a Master of Music from the Eastman School of Music, and a Master of Business Administration from Harvard Business School.
Weidemanis joined Danaher in 2011. Among his many accomplishments, he most recently led our Diagnostics businesses and previously oversaw our Product Identification and Water Quality platforms, which are now part of Veralto Corporation.
